Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
About
Explore Content
For Authors
Alert & RSS Feed
About
Explore Content
For Authors
Alert & RSS Feed
Guangdong Provincial People’s Hospital, Guangzhou, China
Xueqing Yu is the Preisdent of Guangdong Provincial People’s Hospital. His research interests include genetic pathogenesis of IgA nephropathy and peritoneal dialysis. Prof. Xueqing Yu has published 127 peer-reviewed articles in J Am Soc Nephrology, Kidney Int, Am J Kidney Disease in the past 5 years. He has made other major achievements on management in lupus nephritis, mechanisms of renal fibrosis and COVID-19 associated acute kidney injury.
Ye-Guang Chen, Tsinghua University/Nanchang University, Beijing, China
Liming Liang, Harvard University, Massachusetts, USA
Huiying Liang, Guangdong Provincial People's Hospital, Guangdong, China
Professor Huiying Liang is the Founding Director of the Bio-Med Big Data Center at Guangdong Academy of Medical Sciences. Professor Liang is a trained epidemiologist and has a major interest in the transformation and application of medical big data in medical artificial intelligence. His team has formed a series of core AI related technologies in NLP and text analysis, medical image processing, cross-modal analysis reasoning, etc. Leading the team to host 4 national key R & D projects related to medical artificial intelligence, published more than 180 papers and applied for 10 invention patents, and 12 software copyrights. Among them, the representative journals include 3 "Cell" and 2 "Nature Medicine". Awarded with the Guangzhou high-level talents, Guangzhou key medical talents, Guangong Provincial Special plan young top-notch talent, and winners of Excellent youth fund of NSF.
Ji-Feng Fei, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Ji-Feng Fei is from Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences. He is Guangdong Pearl River Scholar Distinguished Professor, member of the Youth Committee and Developmental Biology Committee of the Chinese Society for Cell Biology. He received his PhD degree from the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG). He has long been engaged in using animal organisms to generate disease models to study the mechanisms of organ development and regeneration. In recent years, he mainly focused on a vertebrate model Mexican axolotls to elucidate its molecular and cellular mechanisms of tissue regeneration using functional genomics, single-cell sequencing, spatial transcriptomics, living-imaging and drug screening approaches, which may provide feasible strategies to improve limited regenerative capacity in mammals. His research works were published in peer reviewed journals, including Nature, Science, Nature Commun, Nature Protoc, PNAS, PLoS Biol and Cell Rep.
Haitao Li, PhD, Tsinghua University, Beijing, China
Dr. Haitao Li received his bachelor’s degree in microbiology from Shandong University in 1997 and his doctorate degree in molecular biophysics at the Institute of Biophysics, Chinese Academy of Sciences in 2003. He then performed his postdoctoral research at Memorial Sloan-Kettering Cancer Center and was promoted to Senior Research Scientist in 2006. Li joined the School of Medicine at Tsinghua University as a tenure-track associate professor in 2010 and became full professor with tenure in 2016. Dr. Li currently serves as associate director of Beijing Frontier Research Center of Biological Structure and associate dean of School of Medicine, Tsinghua University. His research is focused on gaining molecular and mechanistic insights into epigenetic regulation impacting on human health and disease. His major contribution to science has been the elucidation of the molecular basis underlying modification-dependent histone/DNA recognition and catalysis by epigenetic factors, such as PHD finger and YEATS domains. Dr. Li has authored more than 100 scientific publications that have received over 14,000 citations. He is the recipient of numerous awards, including the CC Tan Life Science Innovation Award, Promega Innovation Award for Cell Biology, the Young Scholar of China Award in Cancer Research, the Wuxi PharmaTech Life Science and Chemistry Awards, Mao Yi-sheng Science and Technology Award for Beijing Youth, the HFSP Young Investigators Grant Award, and the National Science Fund for Distinguished Young Scholars of China.
Jian Wu, MD, PhD, Tsinghua University, Beijing, China
Jian Wu, a Distinguished Professor at Zhejiang University. He serves as vice dean of international campus, Zhejiang university and the Director of the Realdoctor AI Healthcare Research Center. His research interests mainly focus on medical artificial intelligence, and he has published over 100 papers indexed by SCI/EI. He has six projects funded by the National Natural Science Foundation. In 2007, he received the First Prize of the Ministry of Education Science and Technology Progress Award. In 2008, he was awarded the First Prize of Zhejiang Provincial Science and Technology Progress Award. In 2009, he received the Special Prize of Science and Technology from the China Federation of Commerce and Industry. In 2010, he was honored with the Second Prize of the National Science and Technology Progress Award. In 2014, he received the First Prize of Zhejiang Provincial Science and Technology Progress Award. In 2018, he was awarded the Second Prize of Zhejiang Provincial Science and Technology Progress Award. In 2021, he received the Excellent Achievement Award in Science and Technology Progress from the China Computer Federation, and in 2022, he received the Second Prize of the Science and Technology Award from the China Electronics Society and the Second Prize of the China Industry-University-Research Collaboration Innovation Achievement Award.
Wenzhao Zhong, MD, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Wenzhao Zhong is Chief of Physician, Thoracic Neoplasms Surgery; Director of Guangdong Lung Cancer Institute; Vice Chairman of Thoracic Surgery Committee of Chinese Research Hospital Association; Member of Chinese Hospital Association Health Data Application and Management Committee; Chief of Lung Cancer Specialist Group of Chinese Society of Clinical Oncology; Judge of National Natural Science Foundation of China; Deputy Leader of the Cancer Early Diagnosis and Treatment Group of Chinese Medical Association; Associate Editor of JTO (J Thorac Oncol, IF 20.1), the Official Journal of the International Association for the Study of Lung Cancer (IASLC). He mainly focus on lung cancer. He also dedicate my time to clinical trials and translational researches including systemic treatment modality of stage III non-small cell lung cancer (NSCLC), personalized perioperative treatment, diagnosis and management of pulmonary nodules as well as early screening of lung cancer.
Rufu Chen, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Professor Rufu Chen is the vice president of Guangdong Academy of Medical Sciences, and is the chief director of pancreatic center of Guangdong Provincial People's Hospital. He is the leader of the national clinical key specialty of general surgery, one of the Top 10 pancreatic surgeons in China’s Hundred Famous Doctors list, and a renowned doctor in Lingnan region. He founded Guangdong province’s earliest pancreatic specialty and has long been committed to the standardized diagnosis and treatment of liver, gallbladder, and pancreatic tumors. He is also the vice-chairman of the Pancreatic Disease Special Committee of the Chinese Medical Association, the vice-chairman of the Pancreatic Cancer Special Committee of the China Anti-Cancer Association, the chairman of the Minimally Invasive and Comprehensive Treatment Branch, the executive deputy editor-in-chief of the Chinese Journal of Pancreatic Diseases, and the president of the Guangdong Medical Association. He was one of the first to propose the radical surgery for pancreatic head cancer with combined neural and lymphatic clearance, which significantly improved the prognosis of patients. He has also established procedural and personalized minimally invasive techniques for pancreatic duodenal resection and pancreatic-intestinal anastomosis using the “three-needle” method. He founded the South China Pancreatic Minimally Invasive Alliance, which has been promoted in more than 300 hospitals across China. He has received 16 national key research and development sub-projects, and has published more than 200 papers in journals such as Nat Commun, Lancet Gastroen Hepatol, and J Clin Invest. His series of achievements, “Establishment and Promotion of Personalized and Precise Diagnosis and Treatment System for Pancreatic Cancer,” won the first prize of the Guangdong Medical Science and Technology Award.
Bing Gu, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Bing Gu Serves as Vice Chairman of the Chinese Medical Association's Youth Committee, Vice Chairman of the Chinese Medical Equipment Association. He Has led five projects funded by the National Natural Science Foundation of China, one National Key Research and Development Program. The researcher has conducted a series of innovative studies on the prevention and control of major infectious diseases and drug resistance mechanisms, developed systematic biological sample libraries based on clinically important pathogenic microorganisms, and pioneered rapid and precise detection methods for a variety of major infectious diseases.
Haixia Guan, MD, PhD, Department of Endocrinology, Guangdong Academy of Medical Sciences, Guangzhou, China
Haixia Guan is a professor and deputy director at the Department of Endocrinology, Guangdong Provincial People’s Hospital, Guangzhou, China. She is member of the American Endocrine Society (TES), American Thyroid Association (ATA) and Asia & Oceania Thyroid Association (AOTA), as well as editorial board member of Thyroid, Clinical Thyroidology, Journal of Clinical Endocrinology & Metabolism and Endocrine. Dr. Guan’s research interests have been management of thyroid disorders, effects of trace elements and vitamins on human health outcomes, endocrine disorders in pregnancy and tumor-related endocrine disorders. She has had more than 100 publications including peer-reviewed articles published in New England Journal of Medicine, JAMA Network Open, Journal of Clinical Endocrinology & Metabolism, Thyroid and Cancer. She was actively involved in several important Chinese guidelines for management of thyroid diseases.
Jie Li, MD, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Jie Li is a Professor of Nutrition and Epidemiology at Guangdong Provincial People's Hospital (GDPH) and Guangdong Academy of Medical Sciences (GAMS), located in Guangzhou, China. He holds the positions of Deputy Director of the Global Health Research Center at GAMS and Deputy Director of the Department of Nutrition at GDPH. In addition, he is an Adjunct Professor of Epidemiology at Brown University in the USA. His expertise in the field of molecular epidemiology of nutrition and related metabolic diseases is widely recognized. He served as a reviewer for over 20 scientific journals, including The American Journal of Clinical Nutrition, for which he was awarded Top Reviewer by the American Society for Nutrition. He has been the principal investigator on 10 research grants, including the prestigious National High-Level Talents Program and the National Natural Science Foundation of China. His research has resulted in over 40 peer-reviewed publications and two book chapters, which have appeared in well-respected journals such as Diabetes Care, Clinical Chemistry, Hypertension, and The American Journal of Clinical Nutrition.
Zhexiong Lian, MD,Guangdong Academy of Medical Sciences, Guangzhou, China
Professor Zhe-Xiong Lian is mainly engaged in the basic immunological research of autoimmune diseases and chronic inflammatory diseases of the liver, as well as the research and development of therapeutic targets and immune drugs. He has made outstanding contributions to the research of primary biliary cholangitis (PBC). He contributed to the discovery of autoantigen-specific CD8+T cells and the development of a variety of transgenic mouse models capable of mimicking bile duct-specific immune injury, serological characteristics, and chronic disease development in human PBC. Use of these mice models and clinical samples, Prof. Lian devoted himself to explore the roles of immune cells (CD8+T cells, B cells, NK cells and NKT cells), cytokines (IL-6, IL-12 and IFN-γ), and chemokine receptors in the pathogenesis of PBC and the role of hematopoietic system abnormality, which greatly promoted the basic and clinical research of PBC, and revealed the immune pathological mechanism of autoimmune liver disease and new strategies for clinical immunotherapy. He also participated in the creation, research and application of key technologies of pathogenesis and diagnosis and treatment of autoimmune diseases and won the first prize of China Medical Science and Technology Award and the first prize of Beijing Science and Technology Award in 2018. Prof. Lian has published more than 160 papers in high quality scientific journals, such as J.Exp.Med., J.C.I., Gastroenterology, Hepatology, Sci. Adv., J. Autoimmun., J. Immunol. etc, and got high international reputation in the field of autoimmune liver disease.
Yong Liu, MD, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Prof Yong Liu is cardiologist in Department of Cardiology, and Director in Cardiorenal research Program Office (CRGD) of Guangdong Provincial Key Laboratory of Coronary Disease, Guangdong Provincil People's Hospital, China. Prof Liu completed Clinical Research Fellow and post-doctor, Duke University (DCRI) and University of Sydney (TGI), as Executive Primary Investigator, Fellow of American College of Cardiology, FACC), He conducts several multicenter clinical trials (e.g.ATTEMPT,GAMI, TIME).
Zaiyi Liu, MD, Department of Radiology, Guangdong Academy of Medical Sciences, Guangzhou, China
Dr. Zaiyi Liu received his Bachelor of Medicine degree from West China University of Medical Sciences in 1999, and received his M.D. degree from Sichuan University in 2004, in Chengdu, Sichuan Province. After M.D. graduation, he served as a residency in Diagnostic Radiology in the First Affiliated Hospital of Wenzhou Medical College in Zhejiang Province. In 2006, he moved to Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences and worked as an attending radiologist in the Department of Radiology. Now he is a Professor of Radiology and PhD Supervisor, and Chairman of the Department of Radiology. Abdominal imaging and Radiomics have been Dr. Liu's primary professional and scientific interests throughout his career as a radiologist. Meanwhile, research of Artificial Intelligence is also among his projects. To date there are 10 scientific research grants in which Dr. Liu is the principal investigator, including The National Science Fund for Distinguished Young Scholars. Dr. Liu has been published over 100 peer-reviewed SCI papers including Journal of Clinical Oncology, Radiology, Lancet digital health, and Clinical Cancer Research, etc. Liu is the Standing committee member of Chinese Society of Radiology.
Liming Nie, PhD, Guangdong Provincial People's Hospita, Guangzhou, China
Liming Nie is a professor and PhD supervisor of Guangdong Academy of Medical Sciences affiliated with Southern Medical University. He edited and co-authored three textbooks on molecular imaging. His laboratory focused on optical molecular imaging technology advancements mainly on broad-spectrum fluorescence imaging, high-speed photoacoustic microscopy, whole-body photoacoustic computed tomography as well as pioneered their panoramic functional and metabolic applications in vivo. He has been granted more than 10 patents from China and United States. The technology has been commercialized by companies world-wide for both preclinical and clinical imaging. He is collaborating with physicians for clinical studies by translating this technology. He has published over 100 peer-reviewed journal articles published in journals including Nat. Biotechnol., Nat. Nanotechnol., Nat. Commun., Radiology, J. Nucl. Med., Cancer Lett., etc. He has delivered more than 20 invited talks in international conferences. His work was cited by Science, Nat. Photonics, Nat. Method, Sci. Transl. Med., Neuron, PNAS, etc. His Google Scholar H-index and citations have reached 45 and 7000, respectively. He has received numerous research funding awards from National Natural Science Foundation of China as well as Ministry of Science and Technology of China. He received ACS Young Scientist Award and first place award of Huaxia medical technology.
Laiyou Wang, PhD, Department of Pharmacy, Guangdong Academy of Medical Sciences, Guangzhou, China
Professor Laiyou Wang is the Deputy Director of Department of Clinical Pharmacy and supervisor of graduate student. He earned his Pharmacogy Ph.D. issued by Sun Yat-sen University in 2006 after the study towards Biopharmaceutics in Franche-Comte University in France, and completed his postdoctoral training in Kansas Medical Center in USA in 2010. He also spend one year in Australia as a visiting scholar fellow . Dr. Wang is interested in the xenobiotics induced organ injury including brain, as well as the underlying mechanism involved in the causal factors, aiming at rational drug use and prevention in clinics.
Wei Yang, PhD, Center of Immunometabolism, Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
Dr. Wei Yang is a cancer immunology professor at Southern Medical University in China. He completed his PhD at the University of Chinese Academy of Sciences. His research focuses on understanding the impact of metabolic regulation on T cell anti-tumor immunity and elucidating the underlying mechanisms. Dr. Yang's laboratory also actively explores new targets and drugs for cancer immunotherapy. He has successfully identified two potential immunotherapeutic drug targets associated with cholesterol metabolism.
Zhiming Ye, MD, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Professor Zhiming Ye is chief of Nephrology Division of Guangdong provincial people’s Hospital. SOCIETY MEMBERSHIPS:
He is mainly engaged in researches on sepsis related AKI, cardio-renal syndrome, vascular access complications of hemodialysis, and has published more than 60 SCI indexed papers.
Honghua Yu, MD, PhD, Guangdong Eye Institute, Department of Ophthalmology, Guangdong Academy of Medical Sciences, Guangzhou, China
Prof. Honghua Yu is the Director of Department of Ophthalmology, Guangdong Provincial People's Hospital; the Outstanding Young Medical Talent of Guangdong Province; Chairman of the Special Committee for the Prevention and Treatment of Eye Diseases of Guangdong Provincial Hospital Association; Vice Chairman of the Ophthalmology Management Branch of Guangdong Medical Industry Association; Project evaluation expert of National Natural Science Foundation of China; Member of the American Society of Retinal Specialists; Member of Ophthalmology section of the Chinese Medical Association. He is highly skilled at managing cataracts and complex retinal diseases and has multiple high-impact publications focusing on novel ocular biomarkers for systemic diseases. He is also the principal investigator of two Provincial-Level Scientific and Technological Progress Awards.
Wei Zhao, PhD,Guangdong Academy of Medical Sciences, Guangzhou, China
Wei Zhao is a scientific researcher at Guangdong Provincial People's Hospital, serving as a doctoral supervisor. In addition, he holds the position of committee member in the Epigenetic Pharmacology Special Committee of the Chinese Pharmacological Society and Vice Chairman of the Guangdong Society for Brain Development and Brain Disease Prevention. His research interests lie in the epigenetic regulatory mechanism that governs the expression programs of oncogenic genes in cancer cells. Their team primarily investigates the roles of histone modification and m6A RNA methylation regulators, exploring their collaborative functions in shaping gene expression programs.
Shilong Zhong, PhD, Department of Pharmacy, Laboratory of Phase I Clinical Trial, and Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Academy of Medical Sciences, Guangzhou, China
Prof. Shilong Zhong is the Deputy Director of the Department of Pharmacy; Director of Laboratory of Phase I Clinical Trials; Deputy Director of Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People's Hospital. He also serve as Vice Chairman of Pharmacoepigenetic Committee of Chinese Pharmacological Society, Standing Committee member and Secretary General of Cardiovascular Pharmacology Professional Committee of Chinese Pharmacological Society, Committee Chairman of Therapeutic Drug Monitoring of Pharmacological Society of Guangdong Province. Prof. Zhong focuses his research on the genetic/epigenetic mechanisms underlying individual differences in efficacy and toxicity of drug therapy for patients with coronary heart disease (CHD) and Cross-omics study of CHD susceptibility and disease progression. He received more than 20 Funds, including the National key research and development program, National Nature Science Foundation of China, Key research and development program of Guangdong Province, China. He has published more than 60 SCI papers, including papers in Clin Transl Med, Nat Commun, Clin Pharmacol Ther, Cell Death Dis, Cell Biosci and iScience as the corresponding or first author.
Qing Zhou, MD, PhD,Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangzhou, China
Qing Zhou is director of Cancer Hospital of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Deputy Director of Guangdong Lung Cancer Institute, Director of Pulmonary Oncology, Department 2 of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, professor of Southern Medical University. She as a clinician, mainly engaged in clinical diagnosis and treatment of lung cancer.
Abdelouahab Bellou, MD, PhD, MSc, HabDir, University of Rennes, Rennes, France
Bradley Bernstein, MD, PhD, Harvard University, Brookline, USA
Kei Hang Katie Chan, Ph.D., City University of Hong Kong, Hong Kong
Danny Chen, PhD, University of Notre Dame, Notre Dame, USA
Liang Chen, PhD, Hackensack Meridian School of Medicine & Hackensack Meridian Health Center for Discovery and Innovation, Nutley, USA
Tianfeng Chen, PhD, Ji'nan University, Guangzhou, China
Wei Chen, MD, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Di Dong, PhD, Institute of Automation, Chinese Academy of Sciences, Beijing, China
Lutao Du, MD, PhD, Shandong University, Jinan, China
Ping Fu, MD, West China Hospital of Sichuan University, Chengdu, China
Feng Gao, PhD, Duke University, Durham, USA
Yang Gong, PhD, UTHealth School of Biomedical Informatics (SBMI), Houston, USA
Douglas Hanahan, PhD, Ludwig Institute for Cancer Research, Lausanne Branch; Swiss Institute for Experimental Cancer Research (ISREC); School of Life Sciences; Swiss Federal Institute of Technology Lausanne (EPFL); Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland
Chuanming Hao, MD, PhD, Fudan University Huashan Hospital, Shanghai, China
Li-Li Hsiao, MD, PhD, Brigham and Women's Hospital, Boston, USA
Tony Hu, PhD, Tulane University, New Orleans, USA
Gang Jin, MD, PhD, Changhai Hospital of Naval Medical University, Shanghai, China
Duk-Hee Kang, MD, PhD, Ewha Womans University, Seoul, Korea
Hui Yao Lan, MBBS, MMed, PhD, Chinese University of Hong Kong, Hong Kong, China
Bob T. Li, MD, PhD, MPH, Cornell University, Memorial Sloan Kettering Cancer Center, New York, USA
Guisen Li, MD, PhD, Sichuan Provincial People's Hospital, Chengdu, China
Philip Li, MD, Chinese University of Hong Kong, Hong Kong, China
Qifu Li, MD, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Ye Li, BS, MS, PhD, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
Yuhui Liao, PhD, Southern Medical University, Guangzhou, China
Hongli Lin, MD, PhD, The First Affiliated Hospital of Dalian Medical University, Dalian, China
Bicheng Liu, MD, PhD, Instittue of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China
Lei Liu, PhD, Fudan University, Shanghai, China
Simin Liu, MD, ScD, Brown University, Providence, USA
Alejandro Lucia, MD, PhD, Universidad Europea de Madrid, Madrid, Spain
Yang Luo, MD, Chongqing University, Chongqing, China
Xiaochao Ma, PhD, Professor of Toxicology, Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy University of Pittsburgh, USA
Carmela P Morales, MD, University Medical Center of El Paso, EL Paso, USA
Abraham N Morse, MD, Tufts University School of Medicine, Boston, USA
David Nikolic-Paterson, PhD, Monash University, Melbourne, Australia
Jacintha O'Sullivan, PhD, Trinity College Dublin, Dublin, Ireland
Alberto Passi, MD, PhD, University of Insubria, VARESE, Italy
Natalia Prevarskaya, PhD, Cell Physiology Laboratory at the University of Lille, Lille, France
Long-Sheng Song, MD, MS, University of Iowa, Iowa, USA
Lin Sun, MD, PhD, Second Xiangya Hospital of central south university, Changsha, China
Cheukchun Szeto, MBChB (Hons) (CUHK), MRCP (UK), MD (CUHK), FRCP (Edin), FRCP (Lond), FHKCP, FHKAM (Medicine), Chinese University of Hong Kong, Hong Kong, China
Alfred Tay, PhD, University of Western Australia, Perth, Australia
Craig Thompson, PhD, Memorial Sloan Kettering Cancer Center, New York, USA
Jinwei Tian, MD, PhD, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Jianxin Wan, MD, PhD, The First Affiliated Hospital of Fujian Medical University, Fujian, China
Jiayi Wang, MD, PhD, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Ying Amanda Wang, MBBS, PhD, FRACP, The George Institute for Global Health, Macquarie University, Sydney, Australia
Muh Geot Wong, PhD, The University of Sydney, Sydney, Australia
Jian Wu, PhD, Zhejiang University, Hangzhou, China
Ying Xian, MD, PhD, FAHA, The University of Texas Southwestern Medical Center, Texas, USA
Gang Xu, MD, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Qi Yang, PhD, MS, MD, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Weiwei Yang, MD, Center for Excellence in Molecular Science, Shanghai, China
Aiming Yu, PhD, University of California, Davis, USA
Hong Zhang, MD, PhD, Renal Division, Peking University First Hospital, Beijing, China
Jianjun Zhang, MD, PhD, MD Anderson Cancer Center, Texas, USA
Li Zhang, PhD, University of New South Wales, Sydney, Australia
Taiping Zhang, MD, PhD, Peking Union Medical College Hospital, Beijing, China
Youcai Zhang, PhD, Pharmacology School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
Jian Zheng, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, China
Lei Zheng, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, USA
Shangyou Zheng, MD, PhD, Guangdong Academy of Medical Sciences, Guangzhou, China
Shougang Zhuang, Md, PhD, Brown University School of Medcine, Providence, USA
Xia Zou, Ph.D., Guangdong Provincial People's Hospital, Guangzhou, China